Jefferies analyst Kelly Shi has initiated coverage on Verastem (VSTM, Financial) with a Buy rating and set a price target of $15. This decision comes as the company approaches a significant regulatory milestone, with the U.S. Food and Drug Administration (FDA) slated to make a decision by June 30 regarding Verastem's treatment for low-grade serous ovarian cancer.
This particular type of ovarian cancer currently lacks approved therapeutic options, highlighting a substantial unmet medical need. Shi's assessment is bolstered by insights from key opinion leaders who express optimism about the drug's potential market acceptance. The enthusiasm is not confined solely to the labeled KRASm patient population but extends to other segments as well, due to the treatment's compelling clinical characteristics.
As Verastem moves toward the FDA's upcoming verdict, investor interest remains heightened, driven by the promising prospects of addressing a critical gap in ovarian cancer treatment.
